BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 160
- Registration Number
- NCT05372354
- Locations
- 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇨🇦University of Alberta - Cross Cancer Institute, Edmonton, Alberta, Canada
🇪🇸ICO - Hospital Germans Trias i Pujol, Barcelona, Spain
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 139
- Registration Number
- NCT05369832
- Locations
- 🇺🇸
Local Institution - 0048, Dothan, Alabama, United States
🇺🇸Local Institution - 0206, Chandler, Arizona, United States
🇺🇸Local Institution - 0216, Gilbert, Arizona, United States
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 158
- Registration Number
- NCT05362045
- Locations
- 🇺🇸
Clinical pharmacology of Miami, Miami, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Ppd Phase I Clinic, Austin, Texas, United States
A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT05350800
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 162
- Registration Number
- NCT05337137
- Locations
- 🇺🇸
Local Institution - 0042, Los Angeles, California, United States
🇺🇸Local Institution - 0039, Los Angeles, California, United States
🇺🇸Local Institution - 0034, San Francisco, California, United States
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT05337345
- Locations
- 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 450
- Registration Number
- NCT05335031
- Locations
- 🇩🇪
Universitätsklinikum Dresden, MS Ambulanz, Dresden, Saxony, Germany
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
- Conditions
- Stomach Neoplasms
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT05334719
- Locations
- 🇯🇵
Local Institution - 0001, Minato-ku, Tokyo, Japan
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 700
- Registration Number
- NCT05328908
- Locations
- 🇧🇪
Local Institution - 0120, Leuven, Belgium
🇨🇭Local Institution - 0057, Aarau, AG, Switzerland
🇧🇪Local Institution - 0070, Edegem, Belgium
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
- Conditions
- Mesothelioma, Malignant
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT05324436
- Locations
- 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan